Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518

被引：0
|
作者：
Rosenstock, Julio [1 ]
机构：
[1] Dallas Diabet Res Ctr, Dallas, TX 75230 USA
来源：
DIABETES CARE | 2021年 / 44卷 / 11期
关键词：
GLARGINE;
D O I：
10.2337/dci21-0004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E196 / E197
页数：2
相关论文
共 50 条
  • [1] Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
    Rosenstock, Julio
    Nino, Antonio
    Soffer, Joseph
    Erskine, Lois
    Acusta, Andre
    Dole, Jo
    Carr, Molly C.
    Mallory, Jason
    Home, Philip
    DIABETES CARE, 2020, 43 (10) : 2509 - 2518
  • [2] Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus
    Davis, Portia N.
    Ndefo, Uche Anadu
    Oliver, Ashley
    Payton, Enryka
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (13) : 1097 - 1103
  • [3] Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks
    Leiter, Lawrence A.
    Gross, Jorge Luiz
    Chow, Francis
    Miller, Diane
    Johnson, Susan
    Ahren, Bo
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (08) : 1283 - 1285
  • [4] Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
    Diamant, Michaela
    Nauck, Michael A.
    Shaginian, Rimma
    Malone, James K.
    Cleall, Simon
    Reaney, Matthew
    de Vries, Danielle
    Hoogwerf, Byron J.
    MacConell, Leigh
    Wolffenbuttel, Bruce H. R.
    DIABETES CARE, 2014, 37 (10) : 2763 - 2773
  • [5] Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Maiorino, Maria Ida
    Chiodini, Paolo
    Bellastella, Giuseppe
    Capuano, Annalisa
    Esposito, Katherine
    Giugliano, Dario
    DIABETES CARE, 2017, 40 (04) : 614 - 624
  • [6] Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy
    Shubrook, Jay H.
    JOURNAL OF FAMILY PRACTICE, 2018, 67 (08): : S49 - S54
  • [7] Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial
    Lin, Lu
    Xu, Xiangjin
    Yu, Yunjie
    Ye, Hongjiang
    He, Xiaoqiong
    Chen, Shengping
    Chen, Xaingqi
    Shao, Zhulin
    Chen, Pin
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1428 - 1434
  • [8] Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
    Nino, Antonio
    Okuda, Inaha
    Wilson, Timothy H.
    Yue, Lynn
    Nakajima, Hiromu
    Tsuboi, Maho
    Carr, Molly C.
    Seino, Yutaka
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (03): : 558 - 566
  • [9] Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes
    Kuhadiya, Nitesh D.
    Prohaska, Ben
    Ghanim, Husam
    Dandona, Paresh
    DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 1054 - 1057
  • [10] Efficacy and safety of IDegLira (combination of insulin degludec and liraglutide) in insulin-naive patients with Type 2 diabetes inadequately controlled on glucagon-like peptide-1 receptor agonist(GLP-1RA) therapy
    Viljoen, A.
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J-P
    Handelsman, Y.
    Lehmann, L. M.
    Mishra, A.
    Simpson, R. W.
    DIABETIC MEDICINE, 2016, 33 : 63 - 64
12345